Of note, because of their critical role in the DDR, PARP1 and PARP2 have emerged as important anticancer drug targets, with several PARP inhibitors now used against breast, ovarian, pancreatic and prostate cancers in the clinic [34,35]. Here, PARP1 is linked to prostate carcinoma.